63 results on '"Muss, Hyman B."'
Search Results
2. Breast Cancer Survivor Compliance And Satisfaction With A Community-based Exercise Program: Implications For Future Design: 1769 Board #363 May 28 9:30 AM - 11:00 AM
3. MONOCYTE FUNCTION FOLLOWING ACUTE EXERCISE IN BREAST CANCER SURVIVORS BEFORE AND AFTER EXERCISE TRAINING: 490 Board #306 May 27 9:30 AM - 11:00 AM
4. The Effects Of 16-weeks Of Exercise Training On Neutrophil Functions In Breast Cancer Survivors: 115 May 27 9:45 AM - 10:00 AM
5. Community-Based Exercise Improves Cancer-Related Fatigue and Physical Fitness In Breast Cancer Survivors: A Preliminary Analysis: 3170 Board #216 May 31 3:30 PM - 5:00 PM
6. Physiological Fitness Efficiency of Breast Cancer Survivors Improves Despite Maintenance of Aerobic Capacity: Preliminary Analysis: 947 Board #181 May 29 3:30 PM - 5:00 PM
7. Self-Reported Physical Activity at Breast Cancer Diagnosis is Associated with Greater Physical Activity During Chemotherapy: 2872 Board #155 June 1 2: 00 PM - 3: 30 PM
8. Preliminary Results of Vascular Function and Aerobic Capacity Profile of Breast Cancer Survivors: 2208 Board #44 June 1 11: 00 AM - 12: 30 PM
9. Comparative “nocebo effects” in older patients enrolled in cancer therapeutic trials: Observations from a 446‐patient cohort
10. Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?: A Review
11. Vaginal Estrogens and Aromatase Inhibitors: How Safe Is Safe Enough?
12. Physical activity communication between oncology providers and patients with early-stage breast, colon, or prostate cancer
13. African American Cancer Survivors: Do Cultural Factors Influence Symptom Distress?
14. Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer
15. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
16. Treatment of metastatic breast cancer in women aged 65 years and older
17. Biological, Clinical, and Psychosocial Correlates at the Interface of Cancer and Aging Research
18. Accuracy and Outcomes of Screening Mammography in Women With a Personal History of Early-Stage Breast Cancer
19. Discrepancy Between Preference and Actual Adjuvant Therapy for Breast Cancer
20. Case 15–2010: Mammography in Elderly Women
21. Case 15-2010: An 85-Year-Old Woman with Mammographically Detected Early Breast Cancer
22. Chemotherapy in Older Women with Breast Cancer
23. A Question of Duration: Do Patients with Early-Stage Breast Cancer Need More Than Five Years of Adjuvant Endocrine Therapy?
24. A Question of Duration: Do Patients with Early-Stage Breast Cancer Need More Than Five Years of Adjuvant Endocrine Therapy?
25. Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
26. Extended Adjuvant Endocrine Therapy in Breast Cancer: Current Status and Future Directions
27. Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer
28. Cyclin D-1, Interleukin-6, HER-2/neu, Transforming Growth Factor Receptor-II and Prediction of Relapse in Women with Early Stage, Hormone Receptor-Positive Breast Cancer Treated with Tamoxifen
29. Phase I/II Trial of Adjuvant Dose-Dense Docetaxel/Epirubicin/Cyclophosphamide (TEC) in Stage II and III Breast Cancer
30. Targeted Therapy for Metastatic Breast Cancer
31. American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting
32. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
33. Inadvertent Use of Aromatase Inhibitors in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons
34. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
35. Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen
36. Central Role of the Research Nurse in Improving Accrual of Older Persons to Cancer Treatment Trials
37. Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women
38. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy
39. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
40. Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy
41. Improving Accrual of Older Persons to Cancer Treatment Trials: A Randomized Trial Comparing an Educational Intervention With Standard Information: CALGB 360001
42. ACCO: ASCO Core Curriculum Outline
43. Adjuvant Chemotherapy in Older and Younger Women With Lymph Node–Positive Breast Cancer
44. Recommendations for a Global Core Curriculum in Medical Oncology
45. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer
46. Dose Density by Any Other Name
47. Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041)
48. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
49. Optimizing the Use of Anthracyclines in the Adjuvant Treatment of Early-Stage Breast Cancer
50. Paris and New York: More in Common Than You Think!
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.